[Elsevier] Safety, tolerability, and efficacy of alixorexton, a selective orexin 2 receptor agonist for narcolepsy type 1 (Vibrance-1): a randomised, double-blind, placebo-controlled, phase 2 trial |
|
This post will be closed automatically in 2026-11-01 03:21
Reward20points
|
10
A critical review of the state-of-the-art green ammonia production technologies- mechanism, advancement, challenges, and future potential
10
Improving quality and consumer acceptance of rabbit meat: Prospects and challenges
50
Toward a theory of consciousness: A review of the neural correlates of inattentional blindness
10
Integration of skeletal anchorage and clear aligners in challenging malocclusions: A case series
